|Bid||256.87 x 1100|
|Ask||256.99 x 800|
|Day's Range||256.35 - 261.89|
|52 Week Range||229.40 - 277.29|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||37.43|
|Forward Dividend & Yield||3.48 (1.42%)|
|Ex-Dividend Date||Sep 08, 2022|
|1y Target Est||N/A|
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a collaboration agreement with Labcorp (NYSE: LH), a leading global life sciences company, creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases.
Becton, Dickinson and Company (NYSE: BDX) (the "Company" or "BD") today announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below (collectively, the "Securities" and each a "series").
BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (NACHC), today announced they have awarded four community health centers with a total of $1.08 million to implement programs to support chronic disease management to underserved communities.